Cinobufacini Injection

1. Anti-tumor effect 3g/kg of Cinobufacini has a significant tumor-suppressing effect on mouse transplanted tumors S180 sarcoma and H22 liver cancer, and has a significant tendency to prolong the life of L1210 leukemia mice. The inhibition rate of 7.5g/kg of Cinobufacini on rat W256 is 68.7%. In vitro drug tests show that 2mg/ml of Cinobufacini has a killing effect on three digestive system tumor strains (human liver cancer SMMC-7721, human gastric cancer MKN45, and human colon cancer LOVO), and its mechanism is to directly kill tumor cell DNA and cause tumor cell necrosis. From the molecular level, Cinobufacini has the effect of increasing the cAMP content in the plasma of H22 liver cancer-bearing mice and restoring the cAMP/cGMP ratio to normal. The inhibition rate of Cinobufacini alone on S180 sarcoma mice was 35.5%, and the inhibition rate increased to 71% after combined use with CTX, which was better than CTX alone, indicating that the combined use of Cinobufacini and CTX had a synergistic effect. Clinical data also showed that the combined use of Cinobufacini with 5-Fu, CTX, MTX, and VCR had a synergistic effect. The efficacy of chemotherapy combined with Cinobufacini was significantly improved compared with single drug treatment, and it could reduce the toxic side effects of radiotherapy and chemotherapy. 2. Immunostimulation effect Cinobufacini has a preventive and therapeutic effect on leukopenia caused by CTX, can increase the lymphocyte ratio of mice, and can also increase the content of IgG, IgA, and IgM in mouse serum; experimental data also showed that Cinobufacini has the function of enhancing humoral immunity and cellular immunity. 3. Antiviral effect experiments have shown that Cinobufacini has a significant inhibitory effect on the replication of 2215 cells and duck hepatitis B virus.

This product is an extract from dried toad skin.

This product is a slightly yellow or light yellow clear liquid.

Intramuscular injection: 2-4 ml at a time, twice a day; intravenous drip: 10-20 ml at a time, diluted with 500 ml of 5% glucose injection solution and slowly dripped, take medicine for 7 days, rest for 1-2 days, four weeks as a course of treatment, or follow the doctor's advice.

If the dosage is too large or the interval between two doses is less than 6 to 8 hours, some patients may experience chills and fever about 30 minutes after taking the medicine. A small number of patients may experience local irritation or phlebitis after long-term intravenous infusion, which may slow down the infusion rate. Very few patients may also develop urticaria, dermatitis, etc.

Avoid use with drugs that cause severe cardiotoxicity.

There is no information on the interaction of this product with other drugs.

Keep away from light and in a cool place.

10ml per bottle

36 months

Anhui Huarun Jinchan Pharmaceutical Co., Ltd.

• Founded in:

  2000-07-18

• Address:

  No. 39, Longfa Road, Huaibei City, Anhui Province

• Tax NO.:

  913406007199864132

• Registered Funds:

  165.9 million yuan

• Website:

  Log in to view

• Email:

  Log in to view